BRPI0410653A - composto, composição farmacêutica, e, uso de um composto ou um sal, solvato, hidrato ou n-óxido farmaceuticamente aceitável do mesmo - Google Patents

composto, composição farmacêutica, e, uso de um composto ou um sal, solvato, hidrato ou n-óxido farmaceuticamente aceitável do mesmo

Info

Publication number
BRPI0410653A
BRPI0410653A BRPI0410653-9A BRPI0410653A BRPI0410653A BR PI0410653 A BRPI0410653 A BR PI0410653A BR PI0410653 A BRPI0410653 A BR PI0410653A BR PI0410653 A BRPI0410653 A BR PI0410653A
Authority
BR
Brazil
Prior art keywords
compound
solvate
hydrate
oxide
pharmaceutically acceptable
Prior art date
Application number
BRPI0410653-9A
Other languages
English (en)
Inventor
Daniel Christopher Brookings
Jeremy Martin Davis
Barry John Langham
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0314492A external-priority patent/GB0314492D0/en
Priority claimed from GB0329485A external-priority patent/GB0329485D0/en
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Publication of BRPI0410653A publication Critical patent/BRPI0410653A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, E, USO DE UM COMPOSTO OU UM SAL, SOLVATO, HIDRATO OU N-óXIDO FARMACEUTICAMENTE ACEITáVEL DO MESMO". Uma série de derivados de tieno¢2,3-b!piridin-6(7H)-ona, substituídos na posição 2 por meio de uma pirrolidin-1-ila ligado a carbonila ou sulfonila ou porção relacionada, que são inibidores de p38 MAP quinase, são usados na medicina, por exemplo, no tratamento e/ou na prevenção de distúrbios imunológicos ou inflamatórios.
BRPI0410653-9A 2003-06-20 2004-06-18 composto, composição farmacêutica, e, uso de um composto ou um sal, solvato, hidrato ou n-óxido farmaceuticamente aceitável do mesmo BRPI0410653A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0314492A GB0314492D0 (en) 2003-06-20 2003-06-20 Chemical compounds
GB0329485A GB0329485D0 (en) 2003-12-19 2003-12-19 Chemical compounds
PCT/GB2004/002621 WO2004113347A1 (en) 2003-06-20 2004-06-18 Thienopyridone derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0410653A true BRPI0410653A (pt) 2006-07-04

Family

ID=33542685

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410653-9A BRPI0410653A (pt) 2003-06-20 2004-06-18 composto, composição farmacêutica, e, uso de um composto ou um sal, solvato, hidrato ou n-óxido farmaceuticamente aceitável do mesmo

Country Status (12)

Country Link
US (1) US7521460B2 (pt)
EP (1) EP1641804A1 (pt)
JP (1) JP2007516161A (pt)
KR (1) KR20060021905A (pt)
AU (1) AU2004249495A1 (pt)
BR (1) BRPI0410653A (pt)
CA (1) CA2528602A1 (pt)
EA (1) EA010297B1 (pt)
IL (1) IL172132A0 (pt)
MX (1) MXPA05013227A (pt)
NO (1) NO20060279L (pt)
WO (1) WO2004113347A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0214268D0 (en) * 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
GB0218800D0 (en) * 2002-08-13 2002-09-18 Celltech R&D Ltd Chemical compounds
CA2528603A1 (en) * 2003-06-20 2004-12-29 Celltech R & D Limited Thienopyridone derivatives as kinase inhibitors
JP2007509123A (ja) * 2003-10-24 2007-04-12 セルテック アール アンド ディ リミテッド キナーゼ阻害剤としてのチエノ−ピリジノン誘導体
ES2600460T3 (es) 2005-05-10 2017-02-09 Intermune, Inc. Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés
SI1934174T1 (sl) * 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
KR20080076968A (ko) * 2005-11-23 2008-08-20 인터뮨, 인크. 스트레스-활성화 단백질 키나제 시스템을 조절하는 방법
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
CA2651898A1 (en) 2006-04-07 2007-10-18 Develogen Aktiengesellschaft Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
WO2008064829A2 (en) * 2006-11-30 2008-06-05 Ucb Pharma, S.A. Novel aminothienopyridinone derivatives processes for preparing them and pharmaceutical compositions thereof
PL2101759T3 (pl) 2006-12-14 2019-05-31 Exelixis Inc Sposoby stosowania inhibitorów MEK
WO2008124085A2 (en) * 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
EP2240494B1 (en) 2008-01-21 2016-03-30 UCB Biopharma SPRL Thieno-pyridine derivatives as mek inhibitors
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
UY32072A (es) 2008-08-26 2010-03-26 Boehringer Ingelheim Int Tienopirimidinas para composiciones farmacéuticas
JP5575274B2 (ja) 2010-02-26 2014-08-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物のためのｍｎｋｌ／ｍｎｋ２阻害活性を有する４−［シクロアルキルオキシ（ヘテロ）アリールアミノ］チエノ「２，３−ｄ］ピリミジン
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
MX2012009851A (es) 2010-02-26 2012-09-12 Boehringer Ingelheim Int Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmaceuticas.
EP2598660B1 (en) 2010-07-26 2017-03-15 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
WO2012018639A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
KR102204520B1 (ko) 2012-10-12 2021-01-20 엑셀리시스, 인코포레이티드 암의 치료에 사용하기 위한 화합물의 신규 제조 방법
MX368078B (es) * 2012-11-21 2019-09-17 Zoetis Llc Sintesis de derivados de isoxazolina espirociclicos.
US9725703B2 (en) 2012-12-20 2017-08-08 Biomatrica, Inc. Formulations and methods for stabilizing PCR reagents
WO2015002729A2 (en) 2013-06-13 2015-01-08 Biomatrica, Inc. Cell stabilization
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
ES2786373T3 (es) 2014-06-10 2020-10-09 Biomatrica Inc Estabilización de trombocitos a temperaturas ambiente
KR20250047404A (ko) 2015-12-08 2025-04-03 바이오매트리카 인코포레이티드 적혈구 침강 속도의 감소
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048863A (en) 1994-04-19 2000-04-11 Takeda Chemical Industries, Ltd. Condensed-ring thiophene derivatives and thienopyrimidine derivatives, their production and use
JP2002517486A (ja) 1998-06-12 2002-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター
GB0124848D0 (en) * 2001-10-16 2001-12-05 Celltech R&D Ltd Chemical compounds
GB0214268D0 (en) * 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
GB0218800D0 (en) 2002-08-13 2002-09-18 Celltech R&D Ltd Chemical compounds
CA2528603A1 (en) 2003-06-20 2004-12-29 Celltech R & D Limited Thienopyridone derivatives as kinase inhibitors
JP2007509123A (ja) 2003-10-24 2007-04-12 セルテック アール アンド ディ リミテッド キナーゼ阻害剤としてのチエノ−ピリジノン誘導体

Also Published As

Publication number Publication date
JP2007516161A (ja) 2007-06-21
KR20060021905A (ko) 2006-03-08
NO20060279L (no) 2006-03-20
MXPA05013227A (es) 2006-03-09
CA2528602A1 (en) 2004-12-29
IL172132A0 (en) 2006-04-10
EP1641804A1 (en) 2006-04-05
EA200600064A1 (ru) 2006-08-25
US20070099894A1 (en) 2007-05-03
EA010297B1 (ru) 2008-08-29
AU2004249495A1 (en) 2004-12-29
WO2004113347A1 (en) 2004-12-29
US7521460B2 (en) 2009-04-21

Similar Documents

Publication Publication Date Title
BRPI0410653A (pt) composto, composição farmacêutica, e, uso de um composto ou um sal, solvato, hidrato ou n-óxido farmaceuticamente aceitável do mesmo
ATE402174T1 (de) Imidazopyridinderivate als kinaseinhibitoren
DK0657458T3 (da) Inhibitorer af proteinkinase-C
BRPI0418112A (pt) inibidores de p-38 quinase bicìclico heterocìclicos
DE60311567D1 (de) Trizyklische pyrazolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor mittel
MX2007003319A (es) Derivados heterociclicos y su uso como agentes terapeuticos.
MX9707431A (es) Inhibidores de la proteina cinasa c.
WO2006034446A3 (en) Pyridine derivatives for inhibiting human stearoyl-coa-desaturase
TW200626148A (en) Heterocyclic derivatives and their use as therapeutic agents
ECSP088324A (es) 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidina-5-onas
EP1708686A4 (en) GENERAL LINEAR SHELL FORM OF FENTANYL FOR ORAL USE AND METHOD OF ADMINISTRATION
DK0714392T3 (da) Heterocykliske neurokinin-antagonister
MXPA04001114A (es) Derivados de aminoindazol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
SE0202598D0 (sv) Alpha-7 Nicotinic receptor agonists and statins in combination
ATE352543T1 (de) Ein dioxino(2,3-g)chinolin-9-carbonsäure derivat als nk3 rezeptor antagonist
ATE546452T1 (de) Pyrazolopyrrolderivate als proteinkinaseinhibitoren
NO20054763L (no) Salter av clopidogrel og fremgangsmate for fremstilling derav
CY1109087T1 (el) Ενωση ιμιδαζο[4,5-c]πυριδινης και μεθοδος αντι-ιικης θεραπειας
CY1109939T1 (el) Εκ του στοματος χορηγουμενη μορφη δοσολογιας για ελεγχομενη αποδεσμευση φαρμακου
DK1268472T3 (da) 3-aminopyrazolinhibitorer af cyclinafhængige kinaser
DE60324696D1 (de) Bizyklische heteroaromatische verbindungen als kinase hemmstoffe
EP1613328B8 (en) Use of carbamazepine derivatives for the treatment of agitation in dementia patients
Venisse et al. Rifampicin dramatically decreases clindamycin plasma concentrations in patients treated for bone/joint infections.
NO20091122L (no) Benzo[1,2,3]tiadiazinderivater

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: UCB S.A. (BE)

Free format text: TRANSFERIDO DE: CELLTECH RANDD LIMITED

B25A Requested transfer of rights approved

Owner name: UCB PHARMA S.A. (BE)

Free format text: TRANSFERIDO DE: UCB S.A.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2140 DE 10/01/2012.